End-of-day quote
Nigerian S.E.
18:00:00 2024-05-15 EDT
|
5-day change
|
1st Jan Change
|
1.85
NGN
|
0.00%
|
|
0.00%
|
-4.64%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,347
|
1,177
|
4,235
|
3,324
|
2,716
|
8,290
|
Enterprise Value (EV)
1 |
2,125
|
2,056
|
5,825
|
4,344
|
5,913
|
10,342
|
P/E ratio
|
7.32
x
|
5.35
x
|
19.9
x
|
12.3
x
|
-8.36
x
|
-3.21
x
|
Yield
|
-
|
-
|
2.91%
|
4%
|
-
|
-
|
Capitalization / Revenue
|
0.59
x
|
0.5
x
|
1.49
x
|
1.09
x
|
0.93
x
|
3.75
x
|
EV / Revenue
|
0.94
x
|
0.87
x
|
2.05
x
|
1.43
x
|
2.03
x
|
4.68
x
|
EV / EBITDA
|
5.79
x
|
3.76
x
|
8.42
x
|
6.62
x
|
61.6
x
|
-19.1
x
|
EV / FCF
|
66.7
x
|
-70.2
x
|
-10.6
x
|
-26.4
x
|
-
|
-25.6
x
|
FCF Yield
|
1.5%
|
-1.42%
|
-9.48%
|
-3.79%
|
-
|
-3.91%
|
Price to Book
|
1.37
x
|
1.1
x
|
3.32
x
|
2.35
x
|
3.49
x
|
5.02
x
|
Nbr of stocks (in thousands)
|
1,899,157
|
1,899,157
|
1,899,157
|
1,899,157
|
1,899,157
|
4,273,105
|
Reference price
2 |
0.7091
|
0.6200
|
2.230
|
1.750
|
1.430
|
1.940
|
Announcement Date
|
18-12-18
|
19-12-23
|
20-12-30
|
21-12-29
|
23-03-31
|
24-01-31
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,269
|
2,371
|
2,839
|
3,047
|
2,919
|
2,210
|
EBITDA
1 |
366.8
|
547.6
|
691.8
|
656.7
|
96.02
|
-541.7
|
EBIT
1 |
265
|
444.1
|
581.1
|
548.7
|
-12.39
|
-619.4
|
Operating Margin
|
11.68%
|
18.73%
|
20.47%
|
18.01%
|
-0.42%
|
-28.03%
|
Earnings before Tax (EBT)
1 |
202.5
|
304.4
|
297.4
|
365.3
|
-310.4
|
-2,581
|
Net income
1 |
184
|
220.1
|
212.5
|
270.6
|
-325
|
-2,581
|
Net margin
|
8.11%
|
9.28%
|
7.48%
|
8.88%
|
-11.13%
|
-116.79%
|
EPS
2 |
0.0969
|
0.1159
|
0.1119
|
0.1425
|
-0.1711
|
-0.6039
|
Free Cash Flow
1 |
31.83
|
-29.3
|
-552.1
|
-164.8
|
-
|
-404.1
|
FCF margin
|
1.4%
|
-1.24%
|
-19.45%
|
-5.41%
|
-
|
-18.29%
|
FCF Conversion (EBITDA)
|
8.68%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
17.3%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
0.0650
|
0.0700
|
-
|
-
|
Announcement Date
|
18-12-18
|
19-12-23
|
20-12-30
|
21-12-29
|
23-03-31
|
24-01-31
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
778
|
879
|
1,590
|
1,021
|
3,197
|
2,052
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.121
x
|
1.605
x
|
2.298
x
|
1.554
x
|
33.3
x
|
-3.788
x
|
Free Cash Flow
1 |
31.8
|
-29.3
|
-552
|
-165
|
-
|
-404
|
ROE (net income / shareholders' equity)
|
20.6%
|
22.8%
|
18.1%
|
20.1%
|
-
|
-212%
|
ROA (Net income/ Total Assets)
|
7.22%
|
11%
|
7.9%
|
5.41%
|
-
|
-4.97%
|
Assets
1 |
2,549
|
2,008
|
2,690
|
5,001
|
-
|
51,941
|
Book Value Per Share
2 |
0.5200
|
0.5600
|
0.6700
|
0.7400
|
0.4100
|
0.3900
|
Cash Flow per Share
2 |
0.0200
|
0.0600
|
1.390
|
1.070
|
0.2400
|
0.5000
|
Capex
1 |
188
|
151
|
603
|
344
|
1,270
|
891
|
Capex / Sales
|
8.31%
|
6.36%
|
21.24%
|
11.29%
|
43.49%
|
40.32%
|
Announcement Date
|
18-12-18
|
19-12-23
|
20-12-30
|
21-12-29
|
23-03-31
|
24-01-31
|
Last Close Price
1.85
NGN Average target price
1.75
NGN Spread / Average Target -5.41% Consensus |
1st Jan change
|
Capi.
|
---|
| -4.64% | 5.18M | | +32.75% | 694B | | +29.39% | 593B | | -1.59% | 371B | | +20.09% | 331B | | +6.60% | 290B | | +14.06% | 239B | | -3.15% | 209B | | +9.91% | 209B | | +8.13% | 169B |
Other Pharmaceuticals
|